Clozapine-Induced Myocarditis: Is Mandatory Monitoring Warranted for Its Early Recognition?. (23rd January 2014)

• Record Type: Journal Article
• Authors: Munshi, T. A.; Volochniouk, D.; Hassan, T.; Mazhar, N.
• Other Names: Anghelescu I. G. Academic Editor.; Dell'Osso L. Academic Editor.; Kaneda Y. Academic Editor.; Lançon C. Academic Editor.; Müller N. Academic Editor.; Oyebode F. Academic Editor.
• Is Part Of: Case reports in psychiatry. Volume 2014(2014)
• Publication Date: 2014-01-23
• Subjects: Psychiatry -- Periodicals; Psychiatry -- Case studies -- Periodicals; Mental Disorders; Psychiatry; Psychiatry; Periodicals; Case studies; Periodicals; 616.89
• DOI: 10.1155/2014/513108
• Languages: English
• ISSNs: 2090-682X

Abstract

Abstract : Clozapine is an atypical antipsychotic used for treatment resistant schizophrenia. Its potential to induce agranulocytosis is well known but it can also cause myocarditis. Clozapine is the only antipsychotic known to induce this side effect, typically early in the treatment, and literature is scarce on this condition. We are presenting a case report of a 21-year-old schizophrenic male who developed myocarditis within 3 weeks of starting on clozapine for his treatment resistant psychosis. We then aim to review some of the available literature and raise awareness among physicians as this condition can potentially be fatal if not detected early.